Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cell ImpactOSTO:CI +2.90% Debt-to-Equity is 0.14 as of Jun. 2026, which is at its 10-year median of 0.14. The stock has 7 warning signs investors should review. Among 2,681 Industrial Products companies, Cell Impact ranks better than 67.92% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cell Impact's Debt-to-Equity or its related term are showing as below:
OSTO:CI'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.14 Max: 0.64
Current: 0.14
During the past 13 years, the highest Debt-to-Equity Ratio of Cell Impact was 0.64. The lowest was 0.03. And the median was 0.14.
OSTO:CI's Debt-to-Equity is ranked better than 67.92% of 2681
companies
in the Industrial Products industry
Industry Median: 0.28
vs OSTO:CI: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cell Impact Debt-to-Equity Related Terms
Cell Impact Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cell Impact's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:CI vs CRS, ATI, MLI: Debt-to-Equity Comparison
For the Metal Fabrication subindustry, Cell Impact's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Impact Debt-to-Equity vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Cell Impact's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cell Impact's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Impact (OSTO:CI) has a Debt-to-Equity of 0.14 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cell Impact and its competitors. This is near median its historical median of 0.14. Over the past decade, Cell Impact's Debt-to-Equity has ranged from 0.03 to 0.64. According to the industry distribution chart, Cell Impact ranks #860 out of 2681 companies in the Industrial Products industry, placing it in the top 32.1%.
Is Cell Impact's Debt-to-Equity too high?
Cell Impact's current Debt-to-Equity of 0.14 is near median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.64. The Industrial Products industry median Debt-to-Equity is 0.28. Cell Impact's value of 0.14 is 50% below this industry median. Based on the distribution chart, Cell Impact ranks #860 out of 2681 companies in the Industrial Products industry, which is above the industry midpoint.
How does Cell Impact's Debt-to-Equity compare to CRS and ATI?
According to the Industrial Products industry distribution chart, Cell Impact ranks #860 out of 2681 companies for Debt-to-Equity. This puts Cell Impact in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Cell Impact's value of 0.14 is 50% below this benchmark. Historically, Cell Impact's own Debt-to-Equity has ranged from 0.03 to 0.64 over the past decade. While the company's 10-year median is 0.14 vs. the industry median of 0.28, Cell Impact has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for an Industrial Products company?
The median Debt-to-Equity among Industrial Products companies is 0.28, based on 2,681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cell Impact's current Debt-to-Equity of 0.14 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cell Impact and its competitors. For the Industrial Products industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Impact's current Debt-to-Equity is 0.14, which is near median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Impact stock overvalued right now?
Based on GuruFocus' analysis, Cell Impact (OSTO:CI) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.06 — trading 89.3% above its estimated fair value. The current Debt-to-Equity is 0.14, which is near median its 10-year median of 0.14 and 50% below the Industrial Products industry median of 0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cell Impact (OSTO:CI), the current Debt-to-Equity is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cell Impact develops and manufactures flow plates for fuel cells and electrolyzers using materials such as graphite, stainless steel, and titanium. The company has developed and patented a high-velocity forming method, known as Cell Impact Forming, which enables the production of flow plates with advanced designs. Geographically, it operates in Sweden, Asia, the U.S., and Other Europe. It generates the majority of its revenue from Sweden.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CI has been successfully added to your 
